Keyphrases
30-day Mortality
28%
Adult Patients
16%
All-cause Mortality
12%
Antibiotic Duration
13%
Antibiotic Therapy
21%
Antibiotic Treatment
14%
Antibiotics
24%
Bacteremia
36%
Candida
11%
Clinical Characteristics
15%
Clinical Features
12%
Clinical Outcomes
45%
Clostridioides Difficile
23%
Clostridium Difficile Infection
57%
Clostridium Difficile-associated Diarrhea
21%
Confidence Interval
44%
COVID-19
13%
Difficile
12%
Empiric Antibiotics
11%
Epidemiology
13%
Gram-negative Bacteremia
14%
Hospitalization
14%
Hospitalized Patients
39%
Infective Endocarditis
32%
Influenza
13%
Invasive Pneumococcal Disease
16%
Israel
95%
Klebsiella Pneumoniae (K. pneumoniae)
12%
Klebsiella Pneumoniae Carbapenemase
18%
Long-term Mortality
12%
Lung Transplantation
17%
Methicillin-resistant Staphylococcus Aureus
20%
Mortality Rate
11%
Multivariate Analysis
17%
Mycobacterium Simiae
12%
Nocardiosis
12%
Obesity
12%
Odds Ratio
33%
Pneumonia
15%
Polymerase Chain Reaction
16%
Randomized Controlled Trial
16%
Retrospective Cohort Study
28%
Risk Factors
34%
Single Center
16%
Staphylococcus Aureus
11%
Staphylococcus Aureus Bacteremia
36%
Statins
12%
Tertiary Care Hospital
26%
Trimethoprim-sulfamethoxazole (TMP-SMX)
13%
Vancomycin
27%
Pharmacology, Toxicology and Pharmaceutical Science
All Cause Mortality
20%
Antibiotic Associated Diarrhea
9%
Antibiotic Therapy
16%
Antibiotics
19%
Antiinfective Agent
10%
Bacterial Endocarditis
8%
Bloodstream Infection
52%
Candida
8%
Candidemia
10%
Carbapenem
16%
Carbapenem Resistant Enterobacteriaceae
8%
Case-Control Study
10%
Clostridium Difficile Infection
49%
Cohort Study
28%
Comorbidity
14%
Cotrimoxazole
13%
Diabetes Mellitus
10%
Diarrhea
11%
Diseases
29%
Endocarditis
10%
Extended Spectrum Beta Lactamase
10%
Fluconazole
14%
Gram Negative Bacterium
12%
Gram Negative Sepsis
18%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
12%
Immunocompromised Patient
8%
Infection
92%
Infectious Agent
16%
Klebsiella pneumoniae
14%
Malignant Neoplasm
8%
Methicillin Resistant Staphylococcus Aureus Infection
13%
Methicillin-Resistant Staphylococcus Aureus
15%
Mortality Rate
15%
Multiple Myeloma
8%
Observational Study
13%
Peptoclostridium difficile
16%
Pneumococcal Infection
16%
Prospective Study
7%
Quinolone Derivative
9%
Randomized Controlled Trial
28%
Retrospective Study
29%
SARS Coronavirus
8%
Seasonal Influenza
10%
Soft Tissue Infection
9%
Staphylococcal Bacteremia
28%
Staphylococcus Aureus
17%
Statin (Protein)
9%
Thrombocytopenia
7%
Urinary Tract Infection
10%
Vancomycin
18%
Medicine and Dentistry
All Cause Mortality
14%
Antibiotic Therapy
36%
Antibiotic-Associated Diarrhea
9%
Antibiotics
16%
Antiinfective Agent
8%
Bloodstream Infection
33%
Cancer
8%
Candidemia
8%
Carbapenem
12%
Clostridium Difficile Infection
42%
Cohort Analysis
8%
Comorbidity
8%
Diabetes Mellitus
8%
Diarrhea
16%
Diseases
15%
Emergency Department
8%
External Otitis
8%
Fluconazole
10%
Gram Negative Sepsis
11%
Gram-Negative Bacteria
11%
Hemodialysis
8%
Immunoaffinity Chromatography
8%
Infection
100%
Infective Endocarditis
24%
Influenza A
11%
Intensive Care Unit
17%
Internal Medicine
8%
Klebsiella pneumoniae
12%
Lung Transplantation
16%
Methicillin Resistant Staphylococcus Aureus
8%
Mortality Rate
17%
Multiple Myeloma
8%
Multivariate Analysis
11%
Mycobacterium simiae
8%
Nocardiosis
12%
Odds Ratio
19%
Pathogen
23%
Peptoclostridium difficile
20%
Pericarditis
8%
Pneumococcal Infection
12%
Polymerase Chain Reaction
17%
Randomized Controlled Trial
13%
Recurrence Risk
8%
Retrospective Cohort Study
17%
Retrospective Study
37%
Seasonal Influenza
9%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Staphylococcal Bacteremia
12%
Staphylococcus Aureus
10%
Urinary Tract Infection
10%
